At the European Cancer Congress (ECC) 2015, Charles Swanton, FRCP, BSc, PhD, of The Francis Crick Institute and Cancer Research UK London Research Institute, London, UK, reviews the emerging understanding of mutational drivers of tumour heterogeneity, including APOBEC-mediated mutagenesis, that could support the development of future therapeutic strategies.
The causes and consequences of tumour evolution and heterogeneity
15 Oct 2015
Oncology
Rate this content's potential impact on patient outcomes
Average rating / 5. Vote count:
No votes so far! Be the first to rate this content.